NASP Launches Website to Combat Harmful DIR Fees Tops SPT Week in Review


Top news of the week from Specialty Pharmacy Times.

5. Treatment-Resistant Breast Cancer May Have Met Its Match with First-In-Class Drugs

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer. Read more…

4. Influenza Triggers Relapse in Multiple Sclerosis

Upper respiratory infections cause immune cells to travel to the brain, prompting multiple sclerosis to relapse. Read more…

3. FDA Approves Acute Lymphoblastic Leukemia Drug

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more…

2. Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx. Read more…

1. NASP Launches Website to Combat Harmful DIR Fees provides education about direct and indirect remuneration fees. Read more…

Related Videos
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny -
Image Credit: © Anastasiia -
LGBTQIA+ pride -- Image credit: lazyllama |
Image Credit: © Анастасія Стягайло -
A panel of 4 experts on breast cancer
breast cancer treatment/Image Credit: © Siam -
Image Credit: © Dragana Gordic -
small cell lung cancer treatment/Image Credit: © CraftyImago -
© 2024 MJH Life Sciences

All rights reserved.